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Summary Inhibition of angiogenesis through blocking of growth factors involved in this process could be a
novel therapeutic approach in several important pathologies, neoplasia among them. Suramin has recently
been described to possess antineoplastic activity in animals and humans, and it has been proposed that an
important role in this activity is played by antagonism of growth factors and especially bFGF. To investigate
this hypothesis in vivo, we used gelatin sponges loaded with bFGF and implanted subcutaneously in mice.
Suramin showed an inhibitory activity on bFGF-induced angiogenesis, whereas it was inactive in the case of
heparin-complexed bFGF. Suramin was also studied in an in vivo model of tumour-induced angiogenesis using
the murine M5076 reticulosarcoma, a tumour producing significant levels of bFGF. Suramin was able to
reduce tumour growth and tumour induced angiogenesis, and exogenous administration of bFGF countered
suramin effects.
Physiologically, angiogenesis (i.e. the formation of new capil-
lary vessels), is an important event in embryonic development
and in the adult female reproductive cycle (Gospodarowicz &
Thakral, 1978). Under pathological conditions neovasculari-
sation occurs during the wound healing process (Knighton,
1981) and in a variety of diseases ranging from diabetic
retinopathy to psoriasis and several types of chronic
inflammations (Goldie, 1969). It has also been shown that
the process of solid tumours growth is angiogenesis-
dependent (Gullino, 1978; Folkman, 1990). Several sub-
stances of different chemical nature and cellular origin,
including growth factors produced by the neoplastic cells
themselves, have been described to be involved in tumour-
induced neoangiogenesis (Shing et al., 1985; Folkman &
Klagsbrun, 1987) by directly and/or indirectly stimulating
endothelial cells proliferation and/or migration (Ausprunk &
Folkman, 1977). One of the better characterised among such
angiogenic factors is basic Fibroblast Growth Factor (bFGF)
(Rifkin & Moscatelli, 1989), whose presence in a large
number of normal and malignant cells is well established,
and that has been implicated as a major contributing factor
in both physiological and pathological neovessel formation
(Folkman et al., 1988; Klagsbrun et al., 1986; Thompson et
al., 1988; Hayek et al., 1987). Since solid tumour growth and
progression are strictly dependent from neovessel formation
(Folkman et al., 1989; Brem et al., 1977) interfering with this
process by counteracting the effect of angiogenic growth
factors could represent a novel and selective therapeutic ap-
proach to malignancy.
Suramin, a polysulphonated trypan red derivative used in
the past as antitrypanosomic agent (Hawking et al., 1987),
has recently generated interest as an antinoplastic agent
(Stein et al., 1989; Myers et al., 1990; La Rocca et al., 1990).
Although it seems likely that other biological activities of
suramin also participate in the antitumoural effect of this
compound (Stein et al., 1989) it has been advanced that an
important role is played by its capacity to interfere with the
activity of various growth factors. In fact, suramin has been
reported to inhibit in vitro the binding of IGF, EGF, PDGF,
IL2, TGF,3 and bFGF (Pollock & Richard, 1990; Hosang,
1985; Mills et al., 1990) to their cell surface receptors through
direct complexation of the growth factors and/or via a
modification of the cell receptor (Coffey et al., 1987). This
activity could explain suramin inhibition of the in vitro
growth of a number of cell lines (Spiegelman et al., 1987;
Pienta et al., 1991; Kim et al., 1991).
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In this study we report that suramin is able to inhibit in
vivo bFGF-induced angiogenesis, and is active in a bFGF-
transducer tumour model.
Materials and methods
Chemicals and reagents
Clinical grade, endotoxin-free human recombinant basic
Fibroblast Growth Factor (bFGF) was produced in the
laboratories of Farmitalia-Carlo Erba (Milano, Italy). Work-
ing solutions of bFGF were prepared from sterile aliquots of
a frozen bulk solution stored at - 80°C; aliquots were
thawed and diluted with PBS (Gibco, Grand Island, NY)
containing 0.1% bovine serum albumin (BSA) (Sigma, St
Louis, MO) immediately prior to use. Porcine intestinal
mucosa and bovine kidney heparan sulphate were obtained
by Sigma Chemical Co. (St Louis, MO). Suramin (Germanin,
Bayer, Germany) was kindly provided by Dr E. Cviktovic
(Institut Gustav Roussy, Paris, France), and dissolved in
water immediately prior to use.
Animals and tumours
Young adult female C3H/HeN and C57B1/6 mice (Charles
River Italy, Calco, CO) weighing 23-25 g, were used.
Animals were housed in plastic cages in temperature and
humidity controlled conditions; food and water were
available ad libitum and a 12 h light/dark schedule was main-
tained. When necessary mice were anesthetised by the i.p.
injection of chloral hydrate at a dose of 0.5 mg g-' of body
weight. The transplantable M5076 murine reticulosarcoma
was originally obtained from the National Cancer Institute
(Frederick, MD) and maintained as previously described
(Talmadge et al., 1981).
Five mice/group for sponge implantation experiments and
ten mice/group for tumour growth assay were used.
bFGFangiogenesis assay
Gelatin sponges (Gelfoam Upjohn, Kalamazoo, MI) cut into
strips (approximately 7 by 10 by 10 mm) under sterile condi-
tions were loaded with 0.25 ml of a PBS/BSA 0.1% solution
supplemented or not with the desired concentrations of
bFGF. A bFGF-heparin or bFGF-heparan sulphate complex
was prepared by coincubating bFAGF and Heparin at a 1:1
ratio or, for heparin sulphate at a 1: 10 ratio, for 2 h at 4°C
in PBS-BSA 0.1%. Sponges were then handled as described
above for bFGF alone. Using aseptic techniques, a 1 cm
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dorsal skin incision was made proximately to the base of the
tail and by gentle dissection with forceps a subcutaneous
pouch fashioned 2-3 cm cephalad to the incision. After
implantation of the sponge into the s.c. pouch, the skin was
sutured. At different times intervals after implantation, mice
were sacrificed, the sponges extracted and prepared for visuil
and histological examinations. Macroscopic angiogenesis was
scored on a 0 (absence of neovessel formation) to 5 scale
taking into account the number, shape -and size of the newly
formed blood vessels. Evaluations were made by a single
observer in a blind manner. For histological examination,
sponges removed from the animals were fixed overnight in
neutral buffered formalin; 2-5jim sections cut crosswise to
the sponge center were stained with hematoxylin and eosin.
The content of hemoglobin (Hb) extracted from individual
sponges was also measured as a parameter of vascularisation
of the implant. Hb was extracted from sponges by 4 h
incubation in 0.1 M ammonia solution, and measured using a
commercial colorimetric assay kit (Merck, Germany).
M5076 Tumour-induced angiogenesis assay
For experiments on tumour-induced angiogenesis, sponges
were loaded with 0.25ml of a cell suspension containing
5 x 105 viable M5076 tumour cells in RPMI 1640 medium.
Tumour cells were obtained from in vitro cultures and their
viability was routinely above 90% as evaluated via trypan
blue exclusion.
Tumour growth assay
The tumour inoculum was of 5 x 105 cells injected s.c.
Tumours diameters were measured twice weekly with calipers
the tumour weight was estimated as the length x (width)2 of
each tumour mass x 0.5 (Geran et al., 1972).
Every experiment was repeated at least three times.
Results
bFGF-induced angiogenesis
bGFG-induced angiogenesis was studied using subcutane-
ously implanted gelatin sponges loaded with concentrations
of bFGF ranging from 0.25 to 10 jig/sponge. A first series of
experiments was performed to define both the bFGF dose
and the observation time for optimal assessment of the
angiogenic response in this model. Table I shows the dose-
dependent angiogenetic effect of bFGF on day 14 after
sponge implant, expressed in terms of angiogenic score. In
animals bearing bFGF-treated sponges, several newly-formed
blood vessels were observed to infiltrate the sponges and
neovascularisation was maximal on 12-15 days from im-
plant. Thereafter, vascularisation gradually decreased,
together with a partial reabsorption of the sponge that occur-
red by day 30-40. The maximal angiogenic response was
obtained with 1Ojig bFGF, whereas a dose of 0.25Ag was
inactive. Control sponges without bFGF were not infiltrated
with blood vessel and their content of Hb was irrelevant.
Visual evaluation was confirmed by the histological examina-
tion (Figure 1). In fact, blood-containing newly formed capil-
laries were observed in the bFGF-treated sponges together
with centripetal infiltration of different cell types,
predominantly neutrophils, macrophages and fibroblasts
(Figure lb). In control sponges no newly-formed capillaries
were detected and only a sparse cellular infiltrate at the
periphery of the implant was observed (Figure la). The
angiogenic response was quantified also by assessing the Hb
content of sponges (Figure 2a). The Hb content in sponges
treated with 10 jig of bFGF was 3-4-fold higher than that of
untreated controls; Hb levels were clearly lower in the
sponges loaded with 2.5 jg of bFGF, whereas in sponges
treated with 0.25 jig of bFGF the values were comparable to
those of control implants.
Since the angiogenic response was most evident at the dose
of 10 fig of bFGF on day 14 after sponge implant, these
conditions were chosen for all further experiments.
The effect of suramin in this model was evaluated by
treating mice with the drug. i.v. 1 day after implantation of
sponges preloaded with 10 lg of bFGF. At 200 mg kg-'
suramin (i.e. the highest drug dose not associated with acute
Table I Angiogenic response induced by bFGF-sponges in mice and
the effect of Suramin treatment
bFGF/sponge Suramin treatment Angiogenic
pg/sponge mg kg-' day score
bFGF 10 + + +
bFGF 2.5 + +
bFGF 0.25 - 0
bFGF 10 200 + I 0
bFGF 10 200 + 7 + + +
bFGF 10 100 +1 +++
Mice bearing bFGF-treated sponges were sacrificed 2 weeks after
the implants to evaluate angiogenesis. Suramin was given i.v.
Figure 1 Hematoxylin eosin stained cross-sections of a, control;
b, bFGF-loaded (10lig) gelfoam sponges and c, bFGF-sponges
from mice treated with suramin (200 mg kg-' on day 1). Figures
refer to sponges obtained 14 days after implant.INHIBITION OF bFGF ACTIVITY BY SURAMIN 369
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8 Table II Effect of suramin on angiogenesis induced by sponges
loaded with complex bFGF-Heparin
bFGF/sponge Suramin treatment Angiogenic
tLg/sponge mgkg-' day score
bFGF 10 - + + +
bFGF 10 200 +1 0
Heparin 10 - 0
bFGF-Heparin 10 - + + + + +
bFGF-Heparin 10 200 + 1 + + + + +
bFGF-Heparin 2.5 - + + + +
bFGF-Heparin 2.5 200 + 1 + + + +
bFGF-Hep bFGF-Hep
10 2.5 ,ug/sponge
Figure 2 a, Hemoglobin content in bFGF-induced angiogenesis.
Systemic treatment with Suramin, 200 mg kg- ' i.v. at day 1 after
implant, reduced hemoglobin content to the control level. The
difference between suramin-treated and 10pl bFGF is significant
as P <0.01 (Student t test). b, Hemoglobin content in bFGF-
Heparin induced angiogenesis. Hb levels are higher in bFGF-
Heparin complex than in bFGF alone, in a dose dependent
manner. Systemic treatment with Suramin, 200 mg kg- ' i.v. at
day 1 after implant, had affected only bFGF-loaded sponges, but
not the bFGF-Heparin loaded sponges. Standard errors do not
exceed 5% of values.
or subacute toxicity), the angiogenic response induced by
bFGF was effectively prevented. Sponges were in fact indi-
stinguishable from controls both at visual inspection and
histological examination, neovessel formation being negligible
and cellular infiltration minimal (Figure Ic). The very low
Hb content of sponges after suramin treatment further
confirmed the absence of angiogenesis (Figure 2a). Con-
versely, suramin dose of 100mg kg-' given at day 1, or a
dose of 200 mg kg- ' administered at day 7, did not
significantly affect neovascularisation in sponges (Table I) as
evaluated histologically or via the Hb content.
bFGF has been demonstrated to interact with heparin
and heparan sulphate forming a complex reported to be
more resistant than bFGF alone to proteolytic degradation
(Saksela et al., 1988; Flaumenhaft et al., 1990). Table II
shows the angiogenic response elicited in sponges pre-loaded
with bFGF complexed with heparin in a ratio of 1:1.
Whereas heparin alone up to 10 plg/sponge had no detectable
angiogenic activity, sponges loaded with the bFGF-heparin
complex induced a much higher angiogenic response in com-
parison to bFGF alone. Angiogenesis with bFGF-heparin
complex was dose dependent in the tested range of 2.5 to
10lg/sponge. Sponges loaded with the bFGF-heparin com-
plex showed at the dose of 10fg of 2-fold higher Hb content
compared to that observed in sponges loaded with bFGF
alone, whereas in sponges loaded with heparin only no Hb
was detected (Figure 2b). Results similar to those obtained
with the heparin complex were obtained complexing bFGF
with heparan sulphate (data not shown).
In contrast to what observed with sponges loaded with
bFGF alone, suramin administered i.v. at 200 mg kg-' at day
1 was unable to inhibit neovascularisation induced by bFGF-
heparin sponges. In fact the angiogenic score (Table II) and
Mice bearing bFGF-treated sponges were sacrificed 2 weeks after
the implant. Suramin was given i.v.
the Hb content of sponges (Figure 2b) were not significantly
modified in comparison to controls.
Tumour-induced angiogenesis
Preliminary experiments in this laboratory had shown that
conditioned medium from cultures of M5076 cells contained
measurable amounts of bFGF and that it was consistently
angiogenic in the rabbit cornea assay. For these reasons the
M5076 tumour was chosen for in vivo studies to investigate
the possible role of bFGF in tumour angiogenesis and to
evaluate the activity of suramin on this process.
In preliminary experiments, different numbers of M5076
tumour cells (from I04 to 106/sponge) were entrapped in
gelfoam sponges and then implanted subcutaneously and
angiogenesis was evaluated at different times after implant.
An inoculum of 5 x IOcells/sponge was chosen for the
subsequent experiments, since it resulted in a clear angiogenic
response detectable already at 5-7 days from implant and
that was maximal on 10-15 days (Figure 3a). Newly formed
blood vessels of various size and length were observed within
the sponge containing the entrapped tumour cells. Admini-
stration of a single dose of 200 mg kg-' i.v. suramin 1 day
after sponge implantation significantly delayed M5076 cells
induced neovascularisation (Figure 3b). In fact, after suramin
treatment, an histologically detectable angiogenesis appeared
only 12-15 days from implant, whereas in untreated control
animals it was already evident at day 5 and maximal on day
15.
The effect of suramin treatment on the in vivo growth of
the M5076 tumour was then investigated and Figure 4a
shows the results of different treatment schedules with this
drug. Single suramin doses of 200 and 150 mg kg-' admini-
stered i.v. 24 h after s.c. tumour transplant were able to
reduce dose-dependently the growth rate of the tumour,
whereas 100 mg kg-' had no significant effect (not shown).
Suramin was active only when administered in the first days
after tumour cell transplantation and in fact, no tumour
growth inhibition was observed when 200 mg kg-' of
suramin was injected on day 10, a time when the tumour was
already palpable.
The growth of the M5076 tumour was enhanced by the
administration of bFGF. In fact, peritumoural injections
with 5fig of bFGF given daily from day 1 after tumour
transplant to day 7, significantly increased tumour growth
(Figure 4b ). In addition, the growth inhibitory effect of
suramin was almost completely counteracted by topical
bFGF treatment. In fact, after 20-24 days from the implant,
tumours in animals treated with suramin and peritumour
bFGF reached the same size as untreated controls.
Discussion
The involvement of bFGF in the angiogenetic process is well
documented by studies showing bFGF stimulation of endo-
thelial cell proliferation and motility in vitro (Folkman et al.,
1988), induction of angiogenesis in the chick embryo
chorioallantoic membrane, and in the rabbit cornea assay370 E. PESENTI et al.
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Figure 3 Tumour-induced angiogenesis in sponges loaded with M5076 cells. An evident angiogenic response is visible after 15 days
from implant of the sponge loaded with M5076 cells. a, Suramin treatment inhibit tumour-induced neovascularisation b.
(Folkman & Klagsbrun, 1987). Mice bearing s.c. gelfoam
sponges loaded with bFGF developed a clear angiogenic
response within the implant. This response was dramatically
reduced by the systemic administration of suramin as deter-
mined by histological and biochemical parameters. In this
model suramin exerted maximal activity if administered on
the first day after implant, whereas no effect was seen if the
compound was given on day 7 at the dose fully inhibitory on
day 1. Taking also in account that suramin is endowed with
an extremely long half-life in the body (Stein et al., 1989),
these findings indicate that in this experimental conditions
suramin interferes preferentially with the initial phases of the
angiogenetic process, whereas it lost effectiveness when the
process was already established. Previous studies (Coffey et
al., 1987) have shown that suramin by binding bFGF pre-
vented the interaction of this growth factor with its receptors.
Moreover, in our hands suramin was not cytotoxic in vitro
for resting or proliferating endothelial cells even after long
(96 h) exposure times. These observations suggest that also in
the in vivo experimental model employed endothelial cells
were not directly affected in their viability by suramin. The
finding that suramin was only active in the early phase of
angiogenesis is a further, albeit indirect, support for the
contention that in the bFGF-sponge model, suramin activity
derives from its capacity to bind and inactivate bFGF, a key
factors in stimulating endothelial cells multiplication and
thus in angiogenesis.
In physiological conditions bFGF present in tissues is
essentially bound to heparan sulphates associated to the ex-
tracellular matrix (Folkman et al., 1988), and is released
complexed to heparan sulphates after degradation of the
extracellular matrix (Saksela et al., 1988). This complex has
been shown to be more resistant to protease degradation and
to better diffuse in the extracellular environment than free
bFGF (Flaumenhaft et al., 1990). In line with the above
observations, the angiogenetic response elicited by bFGF
when complexed to heparin or heparan sulphate was much
higher than seen in sponges with free bFGF. Suramin was
inactive against the bFGF-heparin complex suggesting that
heparin might compete for the binding to bFGF, with a
much higher affinity than suramin. Importantly however,
while the biological functions of bFGF are maintained and
enhanced after binding to heparin, the binding with suramin
impairs bFGF activity.INHIBITION OF bFGF ACTIVITY BY SURAMIN 371
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Figuire 4 Effect of suramin on the growth of s.c. M5076 tumour.
Suramin had maximal activity at the dose of 200mg kg i.v.
Treatment performed at day 10 from tumour implant had no
activity. The differences between suramin 150-200 mgkg' and
controls are significant as P <0.01 (Student t test) a. Exogenous
administration of bFGF (51&g for 7 days) enhanced tumour
growth and impaired Suramin effect. Control animals were
treated with PBS + BSA 0.1% b. Standard errors do not exceed
5% of values.
Since it has been advanced that bFGF plays a key role
also in tumour induced neovascularisation (Folkman et al.,
1988; Klagsbrun et al., 1986), and, as recently described
(Hori et al., 1991; Gross et al., 1990), in tumour growth, it
was ofinterest to investigate suramin in a simplified model of
tumour-associated angiogenesis as that represented by M5076
cells entrapped in gelfoam sponges. Results obtained were
similar to those seen with bFGF sponges since suramin was
effective only when given within 24-48 h after implantation,
i.e. during the early stages of the response.
Suramin was also able to reduce the growth of M5076
tumour transplanted subcutaneously, with the maximal
activity seen administering the compound on the first day
after tumour transplantation. In this sytem, repeated
peritumoural injections of bFGF increased the tumour
growth rate, and significantly reduced the tumour-growth
inhibitory activity of suramin. Since suramin up to the con-
centration of 150figml-' (data not shown) was not cytotoxic
to cultured M5076 cells, the hypothesis can be advanced that
suramin delays M5076 tumour growth not via a direct cyto-
toxicity on neoplastic cells, but indirectly through
interference with neovessel formation elicited by tumour-
produced bFGF. It should be noted however that the role of
other growth factors involved in angiogenesis (e.g. PDGF,
TGFP, etc.), was not evaluated in this study; accordingly it
cannot be excluded that suramin also interferes with their
activity in tumour growth.
In conclusion, these results provide further direct support
to the conclusion that a major component in the antineoplas-
tic activity of suramin may be an interference with neovas-
cularisation induced by growth factors such as bFGF,
produced by the neoplastic cells. Since suramin administra-
tion is associated with important toxicities in both animals
and humans (Stein et al., 1989; La Rocca et al., 1990), the
identification of novel molecules capable of interfering with
tumour-induced angiogenesis, but possessing a more
favourable therapeutic index, could open alternative ap-
proaches to the treatment of solid neoplasms.
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